Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: the evidence for treatment|
|Citation:||International Journal of Evidence-Based Healthcare, 2010; 8(1):18-27|
|Lisa S Jeffs, Plinio R Hurtado, Randall J Faull, Chen Au Peh|
|Abstract:||Antineutrophil cytoplasmic antibody-associated vasculitis is an autoimmune disease involving small to medium blood vessels. It is an uncommon illness, but can have devastating consequences, particularly on kidney function and other vital organs. Exciting progress has been made in the treatment of the disease largely because of international collaboration in randomised clinical trials. Patient survival has improved dramatically with advancements in disease diagnosis and medical treatment. The long-term morbidity from the disease, although improving, remains substantial with up to 10% of survivors requiring dialysis or kidney transplantation. Clinical trials are underway using more specifically targeted immunosuppressants in the hope to improve the long-term patient outcomes. Advancements are also being made in understanding the pathogenesis of the disease and this will further assist disease treatment and outcomes in the future.|
|Keywords:||antineutrophil cytoplasmic antibodies (ANCA); ANCA-associated vasculitis (AAV); microscopic polyangiitis; vasculitis; Wegener's granulomatosis|
|Rights:||© 2010 Blackwell Publishing Ltd.|
|Appears in Collections:||Aurora harvest 2|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.